Twice-Daily Radiation Linked to Better Quality of Life in Lung Cancer Trial

The NRG-LU005 study evaluated adding the immunotherapy drug atezolizumab (Tecentriq) to standard concurrent chemoradiation for limited-stage small-cell lung cancer. While the addition of atezolizumab did not improve overall survival, the trial revealed that twice-daily radiation therapy was associated with significant improvements in patients' quality of life. These secondary findings suggest that radiation dosing schedules may play an important role in treatment outcomes beyond survival metrics. The results highlight the importance of considering patient well-being and functional status alongside traditional survival measures in cancer treatment planning.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: August 30, 2026 at 10:01 AM



